CEACAM6

Across TCGA pan-cancer cohorts, CEACAM6 mass-spec protein differs between tumor and matched normal tissue in 5 of 18 cancer types tested, making tumor–normal expression one of CEACAM6’s most consistent transcriptional readouts.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where CEACAM6 mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types CEACAM6 is over-expressed in tumor, although a few such as LSCC and HNSC show the opposite, repressed pattern.

LSCC, PDAC, and COAD are the cancer types where CEACAM6 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in CEACAM6 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LSCC	Male	II,III,IV	−0.916	<.001	8	view →
PDAC	Female	All	+1.331	<.001	7	view →
COAD	All	III,IV	+0.342	.013	3	view →
LUAD	All	II,III,IV	+0.308	.013	2	view →
HNSC	Male	IV	−0.585	.039	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 5 strongest of 5 lineages.

CEACAM6–LSCC

Open the LSCC breakdown →